The GLCE Knockout Raji Polyclonal Cells represent a polyclonal knockout population generated via CRISPR/Cas9-mediated gene disruption in the human Raji B lymphocyte line, specifically targeting the GLCE locus. The product is supplied as a heterogeneous pool of edited cells, avoiding the artifacts associated with monoclonal selection while providing a robust system for loss-of-function studies of glucuronic acid epimerase. This format is particularly suited for applications requiring representation of natural genetic variability in a lymphoma cell context.
The Raji cell line is an immortalized B lymphocyte derived from a male patient with EBV-positive Burkitt??s lymphoma. These cells are a well-established model for B cell malignancies, retaining key features such as high proliferation rate and expression of B cell surface antigens. Their use in this knockout product allows researchers to examine the impact of GLCE disruption on lymphoma biology within a relevant cellular environment.
The GLCE gene encodes the enzyme that catalyzes the epimerization of D-glucuronic acid to L-iduronic acid along the heparan sulfate chain, a critical modification that enhances proteoglycan flexibility and growth factor binding. This enzyme functions within a biosynthetic complex involving EXT1, EXT2, NDST1, HS2ST1, and HS6ST1, and its activity is essential for fine-tuning the interactions of heparan sulfate with ligands such as FGF2, VEGF, and PDGF. Disruption of GLCE impairs epimerization, leading to a reduction in iduronic acid content and attenuated binding of heparin-binding growth factors. Consequently, downstream signaling cascades, notably the FGF2-FGFR1-Raf-MEK-ERK pathway, are downregulated, resulting in diminished mitogenic and survival outputs.
In the context of Raji lymphoma, loss of GLCE is anticipated to reshape the heparan sulfate landscape, potentially dampening growth factor-driven proliferation and survival programs that sustain malignant B cells. The disruption may also influence B cell receptor signaling and integrin-mediated adhesion processes that rely on heparan sulfate co-receptor functions. By eliminating GLCE activity, this polyclonal knockout model allows for the systematic dissection of glycosaminoglycan-dependent oncogenic mechanisms and the identification of therapeutic vulnerabilities in Burkitt??s lymphoma.
Research applications span functional glycomics, signal transduction studies, and drug screening targeting heparan sulfate-dependent pathways. Compatible assays include RT-qPCR, Western blotting, flow cytometry, TLC disaccharide analysis, FGF2 binding, proliferation, phospho-ERK analysis, migration, and apoptosis assays. The model supports tumor microenvironment investigations and compound evaluation. For further details, contact Ascent Research.
